RxDoctor Payments Data

Arthur Schantz, MD

Family Medicine · Wantagh, NYNPI 1982742755

Payments from drug & device makers

$13,157in general payments, 2019–2025

Across 355 payments — averaging $37.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Amarin Pharma, Inc.$924
  • Bayer$767
  • Harmony Biosciences LLC$641
  • plus $6K from 36 others

What the payments were for

  • Food & beverage$13,128100%
  • Education$290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,157 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$31,353
Medicare patients
49
Services billed
298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide64$102,630
Repatha SureclickEvolocumab37$45,843
DovatoDolutegravir Sodium/Lamivudine12$33,320
NexlizetBempedoic Acid/Ezetimibe29$29,891
FarxigaDapagliflozin Propanediol22$28,104
TrulicityDulaglutide16$27,879
Xigduo XrDapaglifloz Propaned/Metformin28$26,787
VascepaIcosapent Ethyl23$20,111
OzempicSemaglutide15$13,818
EdarbyclorAzilsartan Med/Chlorthalidone11$7,219
Ezetimibe121$3,068
SynthroidLevothyroxine Sodium28$2,777
Eplerenone15$2,261
Rosuvastatin Calcium110$1,409
Nebivolol Hcl30$1,230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$613$130,50880 claims
Esperion Therapeutics, Inc.Nexlizet$445$29,89129 claims
AstraZenecaFarxiga$1,518$28,10422 claims
Novo NordiskOzempic$1,277$13,81815 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$59$7,21911 claims
AbbVieSynthroid$198$2,77728 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$21$26514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.

Other family medicine in Wantagh

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →